AlphaYouPB
Schedule 13G filing
Paradigm Biocapital Advisors LP disclosed a 6.6% stake in Obsidian Therapeutics, Inc. (OBX)
Paradigm Biocapital Advisors LP reported owning 6.6% of Obsidian Therapeutics, Inc. (OBX) (4,101,576 shares) in a Schedule 13G filed Oct 5, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
- Disclosed
- Oct 5, 2026
- Source
- Schedule 13G
From a public Schedule 13G, linked above. Not investment advice, and not a recommendation to buy or sell.